Bibiana Bielekova

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Richard A. Morgan, Nachimuthu Chinnasamy, Daniel Abate‐Daga et al. · Journal of Immunotherapy · 2013 · 1.1K citations · Full text

Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: Results of a phase II clinical trial with an altered peptide ligand

Bibiana Bielekova, Bonnie L. Goodwin, Nancy Richert et al. · Nature Medicine · 2000 · 819 citations

Neurodegenerative Diseases, Encephalitogenic Potential, Neurobiology Of Disease +14

Regulatory CD56 ^bright natural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosis

Bibiana Bielekova, Marta Catálfamo, Susan Reichert-Scrivner et al. · Proceedings of the National Academy of Sciences · 2006 · 586 citations · Full text

Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon β

Bibiana Bielekova, Nancy Richert, T. Howard et al. · Proceedings of the National Academy of Sciences · 2004 · 313 citations · Full text

Neurological Disorder, Immunology, Immune System +17

Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments

Ann Marie Weideman, Marco Aurelio Tapia-Maltos, Kory Johnson et al. · Frontiers in Neurology · 2017 · 292 citations · Full text